Perfil de la empresa · Healthcare

Aurisco Pharmaceutical Co Ltd

605116 · Shanghái
País / Región
China
Empleados
2026
Buffett Score
62/100
Media
Capitalización8152,1 M CNY
Ingresos (TTM)1703,88 M CNY
EBITDA639,07 M CNY
Margen neto21,89 %
ROE14,62 %
PER (TTM)22,05
PER previsto0
BPA0,91 CNY
Rentabilidad por dividendo1,76 %
Rango de 52 semanas17,79 CNY – 34,98 CNY

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women's heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.

Aún no hay análisis sobre este valor en tu idioma.